期刊文献+

不同剂量阿托伐他汀对冠状动脉介入治疗患者的疗效评价 被引量:6

Evaluation of the Efficacy of Different Doses of Atovastatin to Patients after PCI
下载PDF
导出
摘要 经皮冠状动脉介入治疗(PCI)是目前治疗冠状动脉粥样硬化性心脏病(CAHD)的常见方法。而血脂异常与动脉粥样硬化的发生、发展密切相关,因此他汀类药物在CAHD患者支架植入术前、术后的应用具有重要的地位。现就不同剂量阿托伐他汀对PCI患者的疗效进行比较,并对其应用的安全性问题进行阐述。 Percutaneous coronary intervention(PCI)is performed worldwide daily for the symptomatic treatment of patients with coronary arteriosclerotic heart disease(CAHD).However,the occurrence and development of arteriosclerosis is closely related to the dyslipidemia.It is found that statins for CAHD before and after PCI has an important position.Here is to compare the efficacies of different doses of atovastatin,and elaborate their application safety issues.
出处 《医学综述》 2012年第12期1911-1914,共4页 Medical Recapitulate
关键词 阿托伐他汀 冠状动脉粥样硬化性心脏病 经皮冠状动脉介入治疗 降血脂 Atovastatin Coronary atherosclerotic heart disease Percutaneous coronary intervention Lipid-lowering
  • 相关文献

参考文献28

  • 1Pedersen TR, Faergeman O, Kastelein JP, et al. High-dose atorvas- tatin vs usual-dose simvastatin for secondary prevertion after myo- cardial infarction. The IDEAL study : a randomized controlled trial [ J ]. JAMA, 2005,294 ( 19 ) : 2437 -3445.
  • 2Ray KK, Cannon CP. The potential relevance of the multiple lipid independent(pleotropic) effects of statins in the managment of acute coronary syndromes[J]. J Am Coil Cardiol,2005,46(8):1425-1433.
  • 3Albert MA, Danielson E, Rifai N, et al. Effect of statin tbeapy on C- reactive protein levels. The pravastatin inflammation/CRP evalua- tion(PRINCE) : a randomized trial and cohort study[J].JAMA, 2001,286( 1 ) :64-70.
  • 4Pasceri V, Patti G, Nusca A, et al. Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (atorvastatin for reduction of myocardial damage during angioplasty) study [ J ]. Circulation, 2004,110 ( 6 ) : 674-678.
  • 5Patti G, Pasceri V, Colonna G, et al. Atorvastatin pretreatment im- proves outcomes in patients with acute coronary syndromes under- going early percutaneous coronary intervention : results of the AR- MYDA-ACS randomized trim [J].J Am Coil Cardiol, 2007,49 (12) : 1272-1278.
  • 6刘广安,刘峰,陈润祥,程海,刘建平.负荷量阿托伐他汀降低冠状动脉介入术围手术期心血管事件作用和机制的探讨[J].实用临床医药杂志,2011,15(9):20-22. 被引量:10
  • 7Lea AP, McTavish D. Atorvastatin a review of its pharmacology and therapeuticpotential in the management of hyperlipidaemias [ J ]. Drugs, 1997,53 (5) :828-847.
  • 8Levy RI, Troendle AJ, Fattu JM. A quarter century of drug treat- ment of dys lipoproteinemia with a focus on the new HMG-CoA re- ductase inhibitor fluvas tatin [ J]. Circulation, 1993,87 (4 Supp! ) : m45-m53.
  • 9Biasucci LM, Colizzi C, Rizzello V, et al. Role of inflammation in the pathogenesis of unstable coronary artery diseases [ J ]. Scand J Clin Lab Invest Suppl, 1999,230( 1 ) :12-22.
  • 10张晓娟,李保,王敬萍,张悟棠,王日军,雷新宇.不同剂量阿托伐他汀对冠脉介入治疗前后炎症因子的影响[J].中西医结合心脑血管病杂志,2010,8(7):791-792. 被引量:10

二级参考文献71

共引文献688

同被引文献73

引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部